Few cosmetic and industrial chemicals attract as many anxious searches as diethanolamine. Type "diethanolamine" into a search engine and you will quickly encounter phrases like "linked to cancer," "banned in Europe," and "hormone disruptor." These claims circulate widely in consumer media and clean beauty discourse, often stripped of the scientific context that would allow readers to assess them accurately.
This article addresses those concerns directly, drawing on the published assessments of regulatory bodies and independent scientific panels. The goal is not to dismiss safety questions - some of them are legitimate - but to present what the evidence actually shows, what the conditions of concern are, and what the global regulatory framework currently requires. For DEA physicochemical specifications, see our Diethanolamine product page.
Diethanolamine (DEA, CAS 111-42-2) is a secondary amine produced by reacting ethylene oxide with ammonia. Its molecular formula is C₄H₁₁NO₂ and molecular weight is 105.14 g/mol. At room temperature it is a colourless to pale yellow viscous liquid or white solid (melting point ~28 °C). It is fully miscible with water and widely used as a surfactant intermediate, pH adjuster, gas treatment solvent, corrosion inhibitor, and pharmaceutical excipient.
In personal care products, DEA appears both as a free amine (as a pH adjuster) and as a fatty acid amide derivative - most commonly cocamide DEA - which is a distinct compound with its own INCI listing and regulatory treatment.
🔬 The Cancer Question: What the Evidence Actually Shows
The cancer concern around DEA has two separate threads that are often conflated in popular reporting: the IARC classification of DEA itself, and the formation of N-nitrosodiethanolamine (NDELA) as a reaction product in certain formulations. Understanding the distinction between these two issues is essential for an accurate risk assessment.
IARC Group 2B: What It Means (and What It Doesn't)
The International Agency for Research on Cancer (IARC) classified diethanolamine as a Group 2B carcinogen - "possibly carcinogenic to humans" - in its 2013 monograph review. This classification was based on sufficient evidence of carcinogenicity in animals (primarily rodent skin painting and oral dosing studies) combined with inadequate evidence in humans.
| IARC Group | Classification | Basis | Examples |
|---|---|---|---|
| Group 1 | Carcinogenic to humans | Strong human evidence | Asbestos, tobacco smoke, benzene |
| Group 2A | Probably carcinogenic | Limited human + strong animal | Red meat, glyphosate, acrylamide |
| Group 2B ← DEA | Possibly carcinogenic | Animal evidence; inadequate human data | DEA, aloe vera extract, pickled vegetables, coffee (de-listed 2016) |
| Group 3 | Not classifiable | Inadequate evidence overall | Tea, fluorescent lighting, mercury (inorganic) |
It is important to note that Group 2B is the lower of the two "possible" categories and encompasses over 300 agents including coffee (formerly), aloe vera whole leaf extract, and talc-based body powder. A Group 2B classification does not mean that a substance causes cancer in humans at typical exposure levels - it means that the available data are suggestive but not conclusive.
The animal studies that prompted the 2B classification used dermal application at doses significantly higher than those encountered in cosmetic use, and the mechanism proposed - choline depletion affecting cell signalling - has not been confirmed to operate at human cosmetic exposure levels.
The NDELA Issue: A Separate and More Established Concern
The more robustly established concern is not DEA itself, but its potential reaction with nitrosating agents in cosmetic formulations to form N-nitrosodiethanolamine (NDELA). NDELA is a Group 2A carcinogen (probably carcinogenic to humans) - a full step higher on the IARC scale than DEA itself.
When DEA (a secondary amine) is present in the same formulation as a nitrosating agent - typically certain preservatives such as bronopol (2-bromo-2-nitropropane-1,3-diol), imidazolidinyl urea, or sodium nitrite - a reaction can occur that converts the DEA to NDELA over time, particularly at elevated storage temperatures or low pH. NDELA has demonstrated carcinogenicity in multiple animal species and is classified as a probable human carcinogen by IARC. This is the reaction that drives the regulatory restrictions on DEA in cosmetics, not the DEA classification per se.
The critical distinction: DEA in a well-formulated product that does not contain nitrosating agents does not generate NDELA. The hazard is a formulation chemistry problem, not an intrinsic property of DEA in all conditions.
🌍 Global Regulatory Status of DEA
The regulatory treatment of DEA varies significantly by jurisdiction and by intended application. The following summarises the current status across major markets.
🇪🇺 European Union - EU Cosmetics Regulation (EC No 1223/2009)
Both DEA and its derivatives must not be combined with nitrosating systems. Products must not contain nitrosamines above 50 µg/kg. The EU's Scientific Committee on Consumer Safety (SCCS) has conducted multiple reviews of DEA and cocamide DEA, most recently confirming the restrictions based on the potential for nitrosamine formation in combination with certain preservatives.
🇺🇸 United States - FDA and California Prop 65
At the federal level, the US FDA does not prohibit DEA or cocamide DEA in cosmetics but has issued a consumer advisory noting its concern about the potential for nitrosamine formation and recommending that consumers reduce their exposure. The FDA has not established a maximum concentration limit for DEA in cosmetics under federal law.
Diethanolamine is listed under California's Safe Drinking Water and Toxic Enforcement Act (Proposition 65) as a substance known to the State of California to cause cancer. Products sold in California that expose consumers to DEA above the established safe harbour level (currently no NSRL established for dermal exposure) may require a Prop 65 warning. Brands selling into California should obtain legal guidance on their specific DEA-containing formulations.
🇨🇳 China - NMPA Cosmetic Regulations
China's National Medical Products Administration (NMPA) permits diethanolamine in cosmetics as a pH adjuster and co-surfactant, subject to the general requirement that finished products must not contain N-nitrosamines above 50 µg/kg (consistent with EU limits). Cocamide DEA is permitted as a rinse-off surfactant. China's 2021 Cosmetic Supervision and Administration Regulation (CSAR) introduced enhanced safety assessment requirements, and brands should ensure DEA-containing formulations are supported by up-to-date safety assessment documentation.
🌏 ASEAN, Japan, South Korea
ASEAN Cosmetic Directive and Japan's quasi-drug / cosmetic regulations generally follow EU precedent with respect to DEA, allowing limited use in rinse-off products with nitrosamine controls. South Korea's Ministry of Food and Drug Safety (MFDS) applies similar restrictions to those in the EU. In practice, brands formulating for global distribution typically apply EU-level restrictions across all markets as the most conservative common standard.
Regulatory Summary Table
| Market | DEA (free amine) - Leave-on | DEA (free amine) - Rinse-off | Cocamide DEA - Rinse-off |
|---|---|---|---|
| EU | ⛔ Prohibited | ⚠️ Max 5% | ⚠️ Max 10% |
| USA (Federal) | ⚠️ No limit; advisory only | ⚠️ No limit; advisory only | ⚠️ No limit; advisory only |
| California (Prop 65) | ⛔ Listed carcinogen; warning may be required | ⛔ Listed; warning may be required | ⚠️ Consult legal counsel |
| China | ⚠️ Permitted; nitrosamine limit applies | ⚠️ Permitted; nitrosamine limit applies | ⚠️ Permitted |
| ASEAN / Japan / Korea | ⚠️ Follow EU-equivalent limits | ⚠️ Permitted with limits | ⚠️ Permitted with limits |
🏭 DEA in Industrial Applications: A Different Risk Context
The safety concerns discussed above apply primarily to consumer cosmetic products, where repeated dermal exposure over years is the relevant exposure scenario. The risk context for industrial users - metalworking fluid operators, cement plant workers, gas treatment engineers - is fundamentally different.
In industrial settings, the primary concerns are:
DEA is classified as a skin sensitiser (Category 1) and causes moderate to severe eye irritation (Category 2A) under GHS. Direct skin contact with undiluted DEA or high-concentration solutions requires chemical-resistant gloves and face shield as minimum PPE. Workplace exposure limit: 2 ppm (8-hour TWA) in most jurisdictions.
DEA has a low vapour pressure at room temperature (0.01 mmHg at 20 °C), which limits inhalation exposure in most applications. However, aerosol generation during metalworking fluid operations can create inhalable droplets. Mist control through enclosure, local exhaust ventilation, and mist suppressants is standard engineering practice.
In metalworking fluids, DEA is susceptible to microbial degradation, which can generate nitrite as a metabolic by-product. If DEA-containing fluids become bacterially contaminated, in-situ nitrosamine formation is possible. Regular fluid maintenance (pH monitoring, biocide top-up, fluid replacement) is essential.
Spent DEA-containing process streams (gas treatment reclaimers, metalworking fluid waste) are classified as hazardous waste in most jurisdictions and must be disposed of through licensed waste contractors. DEA is biodegradable but concentrated aqueous waste requires treatment before discharge.
Diethanolamine is a pre-registered and fully registered substance under REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals). It is currently on the SVHC (Substances of Very High Concern) candidate list for authorisation consideration in certain industrial applications, but is not yet subject to an authorisation requirement. Industrial users in the EU should monitor the ECHA SVHC list for any changes to the authorisation status of DEA in their specific application sectors.
🩺 Skin Sensitisation and Allergic Reactions
Separate from the carcinogenicity discussion, DEA is classified as a skin sensitiser - meaning repeated skin contact can, in susceptible individuals, lead to allergic contact dermatitis. This is relevant for both industrial workers with repeated occupational skin contact and consumers who use DEA-containing personal care products regularly.
The sensitisation rate in the general population is low. European dermatological surveillance data (ESSCA) suggest a patch-test positive rate of approximately 1–2% among patients referred for patch testing - a population already enriched for allergic conditions. In the general population, the rate is lower.
For industrial workers in metalworking environments, occupational dermatitis from metalworking fluid components - including DEA - is a recognised occupational health concern. Skin protection programmes including barrier creams, gloves, and post-work skin care are standard requirements in responsible metalworking operations.
⚖️ Putting the Risk in Context
Media coverage of DEA safety tends to present worst-case scenarios - high-dose animal studies, undiluted substance toxicity data, and the California Prop 65 listing - without the concentration, exposure route, and formulation chemistry context that determines actual consumer risk. A more calibrated picture emerges when these factors are considered together.
- That DEA causes cancer in humans at cosmetic use concentrations
- That DEA is a human carcinogen (it is "possibly" carcinogenic based on animal data only)
- That all DEA-containing products form NDELA (nitrosamine formation requires co-presence of specific nitrosating agents)
- DEA is carcinogenic in rodents at high doses via dermal and oral routes
- DEA reacts with nitrosating agents to form NDELA, a probable human carcinogen
- DEA is a skin sensitiser causing occupational dermatitis in some industrial workers
- The EU has restricted DEA in cosmetics on a precautionary basis
The Cosmetic Ingredient Review (CIR) Expert Panel - the independent US body that assesses cosmetic ingredient safety - concluded that DEA is safe for use in rinse-off cosmetics at concentrations up to 5%, provided the finished product does not contain nitrosating agents. This is a narrower safe-use window than existed before 2013 but is not a prohibition.
For industrial applications - gas treatment, metalworking, cement - the carcinogenicity classification is relevant context but does not prohibit use. REACH compliance, occupational hygiene controls, and appropriate waste management are the operative requirements.
🔄 When to Consider Alternatives to DEA
For formulators and manufacturers who wish to avoid DEA entirely - whether for regulatory compliance, brand positioning, or precautionary reasons - the following substitution strategies are available depending on application.
| Application | DEA Role | Preferred Alternative |
|---|---|---|
| Shampoo / body wash | Foam booster (cocamide DEA) | Cocamide MEA - direct substitution at 110–130% loading |
| Cosmetic pH adjustment | Free DEA as base | Triethanolamine (TEA) or AMP (aminomethyl propanol) |
| Metalworking fluid | Corrosion inhibitor / pH buffer | TEA + borate blends; speciality amine packages; consult fluid supplier |
| Gas treatment (selective) | Selective H₂S absorption | MDEA (methyl diethanolamine) - better selectivity, lower hazard profile |
| Cement grinding aid | Particle dispersion / early strength | TEA (better early strength profile); triisopropanolamine (TIPA) for late strength |
In many cases, particularly for personal care applications, substitution is straightforward and the performance trade-off is minimal. For industrial applications such as metalworking and gas treatment, DEA's specific chemistry often means that substitution requires a more detailed process engineering assessment rather than a simple drop-in replacement.
❓ Frequently Asked Questions
📝 Summary
The safety profile of diethanolamine is more nuanced than most consumer media coverage suggests. DEA carries a Group 2B IARC classification based on animal data, but there is no established causal link to human cancer at cosmetic use concentrations. The more concrete risk - NDELA formation - is a formulation chemistry issue that is entirely avoidable by excluding nitrosating agents from DEA-containing formulations.
The EU has taken a precautionary approach that restricts but does not prohibit DEA in cosmetics. For industrial applications, DEA remains widely permitted and in active use, subject to standard occupational hygiene controls and REACH compliance obligations. Brands and manufacturers who require a clean regulatory path across all markets - including California - will find it simpler to substitute cocamide DEA with cocamide MEA and free DEA with TEA or AMP, both of which carry fewer regulatory complications. For applications where DEA's specific chemistry is essential, it remains available and compliant within defined conditions of use.
Sinolook Chemical supplies diethanolamine (DEA 99%), monoethanolamine (MEA 99%), and triethanolamine (TEA 99%) with full documentation including CoA, SDS, and REACH registration support. All products are available with certified DEA content analysis - essential for cocamide MEA producers and EU cosmetic compliance.
